Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Benitec Biopharma Inc.NASDAQ: BNTC
Other Current Liabilities · Q3 FY2026 · quarter ended Mar 2026
Other current liabilities rises 27.0% from a year ago
Other current liabilities stood at $541K at the end of Q3 FY2026, up 27.0% from a year earlier and up 12.0% from the prior quarter. Over 3 fiscal years it compounded at +2.1% a year.
Context
- Other current liabilities amounted to 0.3% of total assets at the end of Q3 FY2026, down 0.1 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +27.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 426K USD
- Year-over-year change
- -10.3%
- 4-year CAGR
- +11.5%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 426K | -10.3% |
| FY2024 | 2024-06-30 | 475K | +0.6% |
| FY2023 | 2023-06-30 | 472K | +18.0% |
| FY2022 | 2022-06-30 | 400K | +44.9% |
| FY2021 | 2021-06-30 | 276K | — |
Other Current Liabilities vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 other current liabilities of $541K is the 9th highest of the 10 companies compared; the peer median is $8.9M.
- Its year-over-year change of +27.0% is the 6th highest of 10, against a peer median of +71.0%.
- Other current liabilities amounts to 0.3% of total assets for BNTC, versus a peer median of 4.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $39.96M | +71.0% | +74.1% | 7.6% | |
| Dec 2025 | $31.7M | +16.6% | +2.5% | 5.9% | |
| Mar 2026 | $18.15M | +122.3% | +49.7% | 4.3% | |
| Mar 2026 | $10.82M | +2392.6% | +61.4% | 4.0% | |
| Mar 2026 | $8.9M | +326.8% | +235.8% | 3.4% | |
| Mar 2026 | $4.16M | +12.8% | +29.1% | 7.3% | |
| Mar 2026 | $1.37M | +698.3% | — | 0.6% | |
| Mar 2026 | $545K | -36.0% | -49.3% | 3.5% | |
| Mar 2026 | $541K | +27.0% | +2.1% | 0.3% | |
| Mar 2026 | -$2.74M | -231.8% | -0.8% | 2.5% | |
| Peer median (excluding BNTC) | $8.9M | +71.0% | +39.4% | 4.0% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.